Literature DB >> 28149016

Cluster of Differentiation 44 (CD44) Gene Variants: A Putative Cancer Stem Cell Marker in Risk Prediction of Bladder Cancer in North Indian Population.

Archana Verma1, Rakesh Kapoor1, Rama Devi Mittal1.   

Abstract

CD44 is involved in cancer-cell growth, invasion, proliferation and metastasis and is also a causal factor for acquisition of resistance to apoptosis. Therefore we evaluated different SNPs of CD44 gene viz. CD44rs187116 A/G, CD44rs4755392 A/T, CD44rs187115 C/T, CD44rs13347 C/T and CD44 rs353639 G/T for bladder cancer risk in North Indian population. 240 bladder cancer patients and 270 cancer free controls were recruited in this study. Genotyping was done by PCR-RFLP for CD44rs187116 A/G. However, CD44rs4755392 A/T, CD44rs187115 C/T, CD44rs13347 C/T and CD44 rs353639 G/T were genotyped by allelic discrimination Taqman® assay. Statistical analysis was done by SPSS. In-silico analysis was done using F-SNP. We found reduced risk in variant genotype, TT of rs4755392 (p = 0.011) as well as in variant allele, T (p = 0.045). No risk was seen in rs13347, heterozygous genotype, CT (p = 0.023) and variant allele, T (p = 0.007). The dominant model, CT + TT also revealed reduced risk (p = 0.009). A marginal risk was seen in dominant model, GT + TT of rs353639 (p = 0.044) and reduced risk in variant allele T (p = 0.040). A significant manifold risk was seen in smokers carrying variant genotype, TT of CD44rs353639 G/T (p = 0.038, OR 1.960). Haplotypic analysis revealed significant association in 4 sets viz. TCCGG p = 0.005, TTCGA p = 0.039, ACTGG p = 0.008 and TCTGA p = 0.006. In-silico analysis using F-SNP, showed altered transcriptional regulation for rs187115, rs13347 and rs353639. Our study suggests that rs353639 shows a marginal risk for bladder cancer susceptibility, whereas rs4755392 and rs13347 have reduced risk of bladder cancer and rs187115 and rs187116 had no effect on bladder cancer susceptibility in North Indians.

Entities:  

Keywords:  BC; BCG immunotherapy; CD44; MIBC; NMIBC

Year:  2016        PMID: 28149016      PMCID: PMC5247376          DOI: 10.1007/s12291-016-0580-y

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  28 in total

1.  shRNA against CD44 inhibits cell proliferation, invasion and migration, and promotes apoptosis of colon carcinoma cells.

Authors:  Yeon Sun Park; Jung Wook Huh; Jae Hyuk Lee; Hyeong Rok Kim
Journal:  Oncol Rep       Date:  2011-11-08       Impact factor: 3.906

2.  Disability adjusted life years for cancer patients in India.

Authors:  Nandagudi Srinivasa Murthy; B S Nandakumar; Sreekantaiah Pruthvish; Preethi Sara George; Aleyamma Mathew
Journal:  Asian Pac J Cancer Prev       Date:  2010

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Common cancer stem cell gene variants predict colon cancer recurrence.

Authors:  Armin Gerger; Wu Zhang; Dongyun Yang; Pierre Bohanes; Yan Ning; Thomas Winder; Melissa J LaBonte; Peter M Wilson; Leonor Benhaim; David Paez; Rita El-Khoueiry; Anthony El-Khoueiry; Michael Kahn; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2011-09-14       Impact factor: 12.531

5.  Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.

Authors:  Thomas Winder; Yan Ning; Dongyun Yang; Wu Zhang; Derek G Power; Pierre Bohanes; Armin Gerger; Peter M Wilson; Georg Lurje; Laura H Tang; Manish Shah; Heinz-Josef Lenz
Journal:  Int J Cancer       Date:  2011-02-11       Impact factor: 7.396

6.  Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer.

Authors:  Y J Guo; G Liu; X Wang; D Jin; M Wu; J Ma; M S Sy
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

7.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients.

Authors:  Yue Qiu; Yuan Hu; Zuo-Yang Zhang; Lei Ye; Fei-Hong Xu; Marion E Schneider; Xue-Ling Ma; Yi-Xin Du; Xian-Bo Zuo; Fu-Sheng Zhou; Gang Chen; Xu-Shi Xie; Yan Zhang; Hong-Zhen Xia; Ji-Feng Wu; Wei-Dong Du
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-10       Impact factor: 4.553

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

10.  CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population.

Authors:  Sonam Tulsyan; Gaurav Agarwal; Punita Lal; Sushma Agrawal; Rama Devi Mittal; Balraj Mittal
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more
  9 in total

Review 1.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

2.  Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.

Authors:  Camilla De Carlo; Marina Valeri; Noemi Rudini; Paolo Andrea Zucali; Miriam Cieri; Grazia Maria Elefante; Federica D'antonio; Rodolfo Hurle; Laura Giordano; Alessandra Bressan; Massimo Lazzeri; Matteo Perrino; Giorgio Guazzoni; Luigi Maria Terracciano; Piergiuseppe Colombo
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

3.  Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer.

Authors:  Ye Liang; Yonghua Wang; Liping Wang; Zhijuan Liang; Dan Li; Xiaoyu Xu; Yuanbin Chen; Xuecheng Yang; Hongbo Zhang; Haitao Niu
Journal:  Bioact Mater       Date:  2020-09-08

4.  Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis.

Authors:  Vishal Chandra; Yun-Mi Lee; Usha Gupta; Balraj Mittal; Jong Joo Kim; Rajani Rai
Journal:  Oncotarget       Date:  2016-11-08

5.  Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility.

Authors:  Tianbiao Zhou; Hong-Yan Li; Wei-Ji Xie; Zhiqing Zhong; Hongzhen Zhong; Zhi-Jun Lin
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

6.  Association of CD44 gene rs187115 polymorphism with colorectal cancer risk and prognosis in Chinese Han population: a case-control study.

Authors:  Qian Wan; Dan Zhang; Qing Zhou; Ming Li; Yujuan Wang; Yang Song; Tianshu Xu
Journal:  Aging (Albany NY)       Date:  2019-11-03       Impact factor: 5.682

Review 7.  Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting.

Authors:  Shweta Bisht; Manisha Nigam; Shyam S Kunjwal; Plygun Sergey; Abhay Prakash Mishra; Javad Sharifi-Rad
Journal:  Stem Cells Int       Date:  2022-06-28       Impact factor: 5.131

8.  CD44 Gene rs8193 C Allele Is Significantly Enriched in Gastric Cancer Patients.

Authors:  Roya Mokhtarian; Hossein Tabatabaeian; Pardis Saadatmand; Mansoureh Azadeh; Negar Balmeh; Bagher Yakhchali; Kamran Ghaedi
Journal:  Cell J       Date:  2019-07-29       Impact factor: 2.479

Review 9.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.